Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 131

1.

Bicyclic Peptides as a New Modality for Imaging and Targeting of Proteins Overexpressed by Tumors.

Eder M, Pavan S, Bauder-Wüst U, van Rietschoten K, Baranski AC, Harrison H, Campbell S, Stace CL, Walker EH, Chen L, Bennett G, Mudd G, Schierbaum U, Leotta K, Haberkorn U, Kopka K, Teufel DP.

Cancer Res. 2019 Feb 15;79(4):841-852. doi: 10.1158/0008-5472.CAN-18-0238. Epub 2019 Jan 3.

PMID:
30606721
2.

Development and dosimetry of 203Pb/212Pb-labelled PSMA ligands: bringing "the lead" into PSMA-targeted alpha therapy?

Dos Santos JC, Schäfer M, Bauder-Wüst U, Lehnert W, Leotta K, Morgenstern A, Kopka K, Haberkorn U, Mier W, Kratochwil C.

Eur J Nucl Med Mol Imaging. 2019 Jan 3. doi: 10.1007/s00259-018-4220-z. [Epub ahead of print]

PMID:
30603987
3.

68Ga-PSMA-11 PET/CT in prostate cancer local recurrence: impact of early images and parametric analysis.

Sachpekidis C, Pan L, Hadaschik BA, Kopka K, Haberkorn U, Dimitrakopoulou-Strauss A.

Am J Nucl Med Mol Imaging. 2018 Oct 20;8(5):351-359. eCollection 2018.

4.

Imaging and radiotherapy for recurrent prostate cancer: An evolutionary partnership.

Murray JR, Kopka K, Afshar-Oromieh A.

Radiother Oncol. 2018 Nov;129(2):387-388. doi: 10.1016/j.radonc.2018.09.016. Epub 2018 Oct 15. No abstract available.

PMID:
30336957
5.

Synthesis, radiosynthesis, in vitro and first in vivo evaluation of a new matrix metalloproteinase inhibitor based on γ-fluorinated α-sulfonylaminohydroxamic acid.

Hugenberg V, Behrends M, Wagner S, Hermann S, Schäfers M, Kolb HC, Szardenings K, Walsh JC, Gomez LF, Kopka K, Haufe G.

EJNMMI Radiopharm Chem. 2018 Jul 27;3:10. doi: 10.1186/s41181-018-0045-0. eCollection 2018 Dec.

6.

Detection efficacy of [18F]PSMA-1007 PET/CT in 251 Patients with biochemical recurrence after radical prostatectomy.

Giesel FL, Knorr K, Spohn F, Will L, Maurer T, Flechsig P, Neels O, Schiller K, Amaral H, Weber W, Schwaiger M, Hohenfellner M, Kratochwil C, Debus J, Haberkorn U, Choyke P, Kramer V, Kopka K, Eiber M.

J Nucl Med. 2018 Jul 24. pii: jnumed.118.212233. doi: 10.2967/jnumed.118.212233. [Epub ahead of print]

PMID:
30042163
7.

Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer.

Afshar-Oromieh A, Debus N, Uhrig M, Hope TA, Evans MJ, Holland-Letz T, Giesel FL, Kopka K, Hadaschik B, Kratochwil C, Haberkorn U.

Eur J Nucl Med Mol Imaging. 2018 Nov;45(12):2045-2054. doi: 10.1007/s00259-018-4079-z. Epub 2018 Jul 7.

8.

68Ga-PSMA-11 PET/CT in Primary and Recurrent Prostate Carcinoma: Implications for Radiotherapeutic Management in 121 Patients.

Koerber SA, Will L, Kratochwil C, Haefner MF, Rathke H, Kremer C, Merkle J, Herfarth K, Kopka K, Choyke PL, Holland-Letz T, Haberkorn U, Debus J, Giesel FL.

J Nucl Med. 2018 Jul 5. pii: jnumed.118.211086. doi: 10.2967/jnumed.118.211086. [Epub ahead of print]

PMID:
29976697
9.

Tracer uptake in mediastinal and paraaortal thoracic lymph nodes as a potential pitfall in image interpretation of PSMA ligand PET/CT.

Afshar-Oromieh A, Sattler LP, Steiger K, Holland-Letz T, da Cunha ML, Mier W, Neels O, Kopka K, Weichert W, Haberkorn U.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1179-1187. doi: 10.1007/s00259-018-3965-8. Epub 2018 Mar 1.

PMID:
29497802
10.

Monomeric and Dimeric 68Ga-Labeled Bombesin Analogues for Positron Emission Tomography (PET) Imaging of Tumors Expressing Gastrin-Releasing Peptide Receptors (GRPrs).

Liolios C, Buchmuller B, Bauder-Wüst U, Schäfer M, Leotta K, Haberkorn U, Eder M, Kopka K.

J Med Chem. 2018 Mar 8;61(5):2062-2074. doi: 10.1021/acs.jmedchem.7b01856. Epub 2018 Feb 22.

PMID:
29432691
11.

Biochemical Recurrence of Prostate Cancer: Initial Results with [18F]PSMA-1007 PET/CT.

Giesel FL, Will L, Kesch C, Freitag M, Kremer C, Merkle J, Neels OC, Cardinale J, Hadaschik B, Hohenfellner M, Kopka K, Haberkorn U, Kratochwil C.

J Nucl Med. 2018 Apr;59(4):632-635. doi: 10.2967/jnumed.117.196329. Epub 2018 Feb 1.

PMID:
29419475
12.

Cytochrome b 5 impacts on cytochrome P450-mediated metabolism of benzo[a]pyrene and its DNA adduct formation: studies in hepatic cytochrome b 5 /P450 reductase null (HBRN) mice.

Reed L, Mrizova I, Barta F, Indra R, Moserova M, Kopka K, Schmeiser HH, Wolf CR, Henderson CJ, Stiborova M, Phillips DH, Arlt VM.

Arch Toxicol. 2018 Apr;92(4):1625-1638. doi: 10.1007/s00204-018-2162-7. Epub 2018 Jan 24.

13.

[18F]PSMA-1007 PET Improves the Diagnosis of Local Recurrence and Lymph Node Metastases in a Prostate Cancer Patient With a History of Bilateral Hip Arthroplasty.

Giesel FL, Will L, Paddubny K, Kremer C, Rathke H, Radtke JP, Kopka K, Haufe S, Haberkorn U, Kratochwil C.

Clin Genitourin Cancer. 2018 Apr;16(2):111-113. doi: 10.1016/j.clgc.2017.11.008. Epub 2017 Dec 6. No abstract available.

14.

Intraindividual Comparison of 18F-PSMA-1007 and 18F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study.

Giesel FL, Will L, Lawal I, Lengana T, Kratochwil C, Vorster M, Neels O, Reyneke F, Haberkon U, Kopka K, Sathekge M.

J Nucl Med. 2018 Jul;59(7):1076-1080. doi: 10.2967/jnumed.117.204669. Epub 2017 Dec 21.

PMID:
29269569
15.

Integration of CT urography improves diagnostic confidence of 68Ga-PSMA-11 PET/CT in prostate cancer patients.

Will L, Giesel FL, Freitag MT, Berger AK, Mier W, Kopka K, Koerber SA, Rathke H, Kremer C, Kratochwil C, Kauczor HU, Haberkorn U, Weber TF.

Cancer Imaging. 2017 Dec 20;17(1):30. doi: 10.1186/s40644-017-0132-6.

16.

PSMA-11-Derived Dual-Labeled PSMA Inhibitors for Preoperative PET Imaging and Precise Fluorescence-Guided Surgery of Prostate Cancer.

Baranski AC, Schäfer M, Bauder-Wüst U, Roscher M, Schmidt J, Stenau E, Simpfendörfer T, Teber D, Maier-Hein L, Hadaschik B, Haberkorn U, Eder M, Kopka K.

J Nucl Med. 2018 Apr;59(4):639-645. doi: 10.2967/jnumed.117.201293. Epub 2017 Nov 30.

PMID:
29191856
17.

Clinical Translation and First In-Human Use of [44Sc]Sc-PSMA-617 for PET Imaging of Metastasized Castrate-Resistant Prostate Cancer.

Eppard E, de la Fuente A, Benešová M, Khawar A, Bundschuh RA, Gärtner FC, Kreppel B, Kopka K, Essler M, Rösch F.

Theranostics. 2017 Sep 26;7(18):4359-4369. doi: 10.7150/thno.20586. eCollection 2017.

18.

Reply: PSMA Ligands for Imaging Prostate Cancer: Alternative Labeling by Complex Formation with Al18F2.

Giesel FL, Kopka K.

J Nucl Med. 2017 Dec;58(12):2041. doi: 10.2967/jnumed.117.198176. Epub 2017 Nov 9. No abstract available.

19.

Carbon ion radiotherapy: impact of tumor differentiation on local control in experimental prostate carcinomas.

Glowa C, Peschke P, Brons S, Neels OC, Kopka K, Debus J, Karger CP.

Radiat Oncol. 2017 Nov 9;12(1):174. doi: 10.1186/s13014-017-0914-9.

20.

Fluorine-18 Prostate-specific Membrane Antigen-1007 Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging in Diagnostics of Local Recurrence in a Prostate Cancer Patient After Recent Radical Prostatectomy.

Paddubny K, Freitag MT, Kratochwil C, Koerber S, Radtke JP, Sakovich R, Kopka K, Giesel FL.

Clin Genitourin Cancer. 2018 Apr;16(2):103-105. doi: 10.1016/j.clgc.2017.09.014. Epub 2017 Oct 5. No abstract available.

Supplemental Content

Loading ...
Support Center